Home CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Neuros Medical Announces Key Milestones in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

January 7, 2021

Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the achievement of two milestones in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study.

Neuros Medical notes QUEST is a 180-subject, randomized, double-blinded, active sham-controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE).  QUEST is designed to assess the safety & effectiveness of the Company’s Altius® High-Frequency Nerve Block system to treat intractable post-amputation pain. Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

In December 2020, an independent Data Monitoring Committee successfully completed the final planned interim safety and futility analysis of 80 subjects at the 90-day primary endpoints.  In addition, despite the ongoing COVID-19 pandemic, QUEST enrollment now exceeds 100 subjects, and the study is on track for completion of enrollment by the Fall of 2021.

“I wish to thank the QUEST investigators and their clinical research teams for a remarkable collective effort during this extremely challenging year,” said Leonardo Kapural MD PhD, Carolinas Pain Institute and National Principal Investigator of the QUEST study. “I believe that the Altius therapy, with its unique mechanism of action achieved with High-Frequency Nerve Block (HFNB), has great potential to become an important treatment option for post-amputation phantom and stump pain.”

“We join Dr. Kapural in expressing gratitude to the QUEST site clinical research teams for their commitment to both the study as well as to the amputee subjects whom they enrolled,” said David Veino, Neuros Medical Chief Operating Officer. “We look forward to completing enrollment this year,  a key milestone in our efforts to develop a promising treatment option for this significant unmet medical need.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version